Zevra Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Zevra Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue23.6127.4610.1628.6513.2912.840.00
Cost of Revenue7.422.170.222.061.312.950.00
Gross Profit16.2025.299.9426.5911.989.890.00
Operating Expenses
Research & Development42.1039.8119.8010.168.3219.4241.76
Selling, General & Administrative54.8734.3115.048.708.4410.8212.51
Operating Expenses103.2074.1234.8419.0116.7631.8954.27
Operating Income-87.00-49.60-24.907.73-4.78-21.99-54.27
Other Income/Expense
Interest Income2.184.541.510.260.090.000.42
Interest Expense7.35-1.500.340.38-7.090.005.47
Other Income/Expense-3.14-0.60-3.0815.87-0.18-2.314.34
Income
Income Before Tax-90.14-46.05-26.81-8.52-12.79-24.54-56.59
Income Tax Expense15.370.00-0.030.03-0.03-0.02-0.13
Net Income-105.51-46.05-26.77-8.56-12.76-24.52-56.47
Net Income - Continuous Operations-105.51-46.05-26.77-8.560.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-76.40-45.04-25.53-7.89-4.51-23.09-50.80
EBIT-90.14-46.05-26.47-8.15-4.78-25.05-51.12
Depreciation & Amortization6.391.010.940.150.271.660.00
Earnings Per Share
Basic EPS-2.00-1.00-1.00-2.00-3.00-1.00-50.00
Diluted EPS-2.00-1.00-1.00-2.00-3.00-1.00-50.00
Basic Shares Outstanding46.2535.4534.4929.773.9829.651.12
Diluted Shares Outstanding46.2535.4534.4929.773.9829.651.12